IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Study of plasma transforming growth factor-β1 level as a useful tumor marker in various cancers

종양 표지 인자로서 혈장 Transforming Growth Factor-β1에 대한 연구

  • Shin, Hoon (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.) ;
  • Lim, Chang Ki (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.) ;
  • Choi, In Young (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.) ;
  • Lee, Doo Yun (Department of Thoracic and Cardiovascular Surgery, Respiratory Center, Yongdong Severance Hospital, College of Medicine, Yonsei University) ;
  • Noh, Dong Yong (Department of General Surgery, College of Medicine, Seoul National University) ;
  • Ryu, Min Hee (Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Lee, Hyo Suk (Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Bang, Yung Jue (Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Park, Jong Sup (Department of Obstetrics and Gynecology, Catholic University Medical College) ;
  • Jin, Seung Won (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.)
  • 신훈 (한미약품 중앙연구소) ;
  • 임창기 (한미약품 중앙연구소) ;
  • 최인영 (한미약품 중앙연구소) ;
  • 이두연 (연세대학교 의과대학 영동세브란스병원 호흡기센타 흉부외과) ;
  • 노동영 (서울대학교 의과대학 일반외과) ;
  • 류민희 (서울대학교 의과대학 혈액종양내과) ;
  • 이효석 (서울대학교 의과대학 소화기내과) ;
  • 방영주 (서울대학교 의과대학 혈액종양내과) ;
  • 박종섭 (가톨릭대학교 의과대학 산부인과) ;
  • 진승원 (한미약품 중앙연구소)
  • Published : 2001.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background : Many investigators have found transforming growth factor-${\beta}1$ (TGF-${\beta}1$) to be elevated in tumors. Changes in responsiveness to TGF-${\beta}1$ have been linked to malignant transformation, tumor progression and tumor regression. Many malignant cell lines of epithelial or hematopoietic origin are refractory to the antiproliferative effects of TGF-${\beta}1$. However, a little is known about the association of TGF-${\beta}1$ with progression of malignant tumor. Methods : In this study, we measured the plasma level of TGF-${\beta}1$ in various cancer patients and evaluated the utility of plasma TGF-${\beta}1$ as a possible tumor marker. Plasma TGF-${\beta}1$ levels were measured using enzyme-linked immunosorbent assay in cancer patients and normal controls. Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) as tumor marker were compared with TGF-${\beta}1$ in the aspects of sensitivity and specificity. Results : The mean of plasma TGF-${\beta}1$ levels was $1.219{\pm}0.834ng/ml$ in normal controls, $5.491{\pm}3.598ng/ml$ in breast cancer, $12.670{\pm}10.386ng/ml$ in lung cancer, $5.747{\pm}3.228ng/ml$ in hepatocellular carcinoma and $10.854{\pm}7.996ng/ml$ in cervical cancer. In comparison with CEA and AFP, TGF-${\beta}1$ is more sensitive. Conclusion : We conclude that the high levels of TGF-${\beta}1$ are common in the plasma of cancer patients. These results suggest that the plasma TGF-${\beta}1$ level can be a potent tumor marker in various cancer patients.

Keywords